Scarica l'app Stockscreener
342.57
0.02%
0.07
Pre-mercato:
343.09
0.52
+0.15%
Precedente Chiudi:
$342.50
Aprire:
$342.68
Volume 24 ore:
328.40K
Relative Volume:
0.72
Capitalizzazione di mercato:
$9.54B
Reddito:
$7.46M
Utile/perdita netta:
$-303.27M
Rapporto P/E:
-25.44
EPS:
-13.4668
Flusso di cassa netto:
$-249.12M
1 W Prestazione:
+8.07%
1M Prestazione:
+14.84%
6M Prestazione:
+95.68%
1 anno Prestazione:
+913.82%
Intervallo 1D:
$339.99
$349.49
Intervallo di 1 settimana:
$314.14
$352.78
Portata 52W:
$32.78
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Nome
Praxis Precision Medicines Inc
Settore
Industria
Telefono
617-300-8460
Indirizzo
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
342.57 | 9.54B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
439.18 | 111.71B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.41 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
834.45 | 51.89B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.94 | 41.49B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
318.07 | 35.31B | 5.36B | 287.73M | 924.18M | 2.5229 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Strong Buy |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-02-02 | Iniziato | Wells Fargo | Equal Weight |
| 2025-12-15 | Reiterato | Oppenheimer | Outperform |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-03 | Reiterato | H.C. Wainwright | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-08-05 | Iniziato | Oppenheimer | Outperform |
| 2024-06-24 | Iniziato | Needham | Buy |
| 2024-06-18 | Iniziato | Guggenheim | Buy |
| 2024-05-01 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-19 | Iniziato | Truist | Buy |
| 2022-06-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | William Blair | Outperform |
| 2020-11-11 | Iniziato | Wedbush | Outperform |
| 2020-11-10 | Iniziato | Cowen | Outperform |
| 2020-11-10 | Iniziato | Evercore ISI | Outperform |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
Praxis Precision gains as lead asset accepted for FDA review - MSN
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $545 - 富途牛牛
Massachusetts Financial Services Co. MA Purchases New Shares in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX) - MSN
Needham Raises Price Target for Praxis Precision Medicine (PRAX) - GuruFocus
Why is Praxis Precision stock soaring Tuesday? - MSN
Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 5.1%Time to Sell? - MarketBeat
Deutsche Bank Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $437 - Moomoo
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $437 From $412, Maintains Buy Rating - marketscreener.com
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - 富途牛牛
PRAX Reiterated by Needham -- Price Target Maintained at $510 - GuruFocus
FDA accepts Praxis Precision Medicines’ NDA for ulixacaltamide in essential tremor By Investing.com - Investing.com South Africa
FDA accepts Praxis Precision Medicines’ NDA for ulixacaltamide in essential tremor - Investing.com Australia
Praxis Precision NDA for Ulixacaltamide in Essential Tremor - TipRanks
FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor - Stock Titan
Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance - Investing.com UK
Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance By Investing.com - Investing.com South Africa
Why Is Praxis Precision Stock Soaring Tuesday? - Benzinga
Jefferies reiterates Praxis Precision Medicines stock rating on FDA review - Investing.com UK
Praxis Precision Medicines stock rating reiterated at Buy by BTIG - Investing.com
Praxis Precision Medicines stock rating reiterated at Buy by BTIG By Investing.com - Investing.com India
Jefferies reiterates Praxis Precision Medicines stock rating on FDA review By Investing.com - Investing.com India
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $510 - Moomoo
Praxis Precision Medicines' (PRAX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application - marketscreener.com
Praxis Precision gets FDA review for lead asset (PRAX:NASDAQ) - Seeking Alpha
Praxis Precision Medicines Announces FDA Acceptance of NDA for Ulixacaltamide HCl for Essential Tremor Treatment, Target Action Date Set for January 29, 2027 - Quiver Quantitative
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor - Bitget
FDA starts Praxis review for essential tremor drug, decision due Jan. 2027 - Stock Titan
(PRAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 - National Today
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $534 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Upgraded to Strong-Buy at Raymond James Financial - MarketBeat
Raymond James Initiates Praxis Precision Medicines at Strong Buy With $815 Price Target - marketscreener.com
Raymond James initiates Praxis Precision Medicines stock coverage with Strong Buy - Investing.com
Raymond James initiates Praxis Precision Medicines stock coverage with Strong Buy By Investing.com - Investing.com South Africa
A Look At Praxis Precision Medicines (PRAX) Valuation After Positive Elsunersen Seizure Reduction Data - simplywall.st
Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway - MSN
PRAX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Wolfe Research Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $500 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $500 to $1,245 - Moomoo
Praxis Adds To Neuroscience Momentum With Epilepsy Trial Success - Citeline News & Insights
H.C. Wainwright reiterates Praxis Precision stock rating on trial data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Praxis Precision stock rating on trial data - Investing.com
HC Wainwright Reiterates Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX) - MarketBeat
HC Wainwright & Co. Reiterates Buy Rating for PRAX with $1245 Ta - GuruFocus
Praxis Precision Medicines Inc Azioni (PRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Praxis Precision Medicines Inc Azioni (PRAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
1.62%
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):